Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 3/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671415 | 0.93 | SCN1A (0.42) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL10552641 | 0.92 | SCN1A (0.45) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL4669222 | 0.90 | CYP2D6 (0.53) | SCN1ASCN2ASCN3ALMNACHRM2 | |
| SCHEMBL4667569 | 0.89 | GAA (0.46) | ALDH1A1 | |
| SCHEMBL22946108 | 0.87 | ALDH1A1 (0.41) | HTTPKMSMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL10577237 | 0.86 | UTS2R (0.41) | LMNACYP1A2CHRM2ADRA2ACYP2D6 | |
| SCHEMBL14380256 | 0.84 | ALDH1A1 (0.40) | SCN1ASCN2ASCN3ALMNACHRM2 | |
| SCHEMBL3684093 | 0.83 | ALDH1A1 (0.41) | HTTPKMKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL4655851 | 0.82 | LMNA (0.44) | LMNAHTTCYP1A2CYP2D6PKM | |
| SCHEMBL7840144 | 0.81 | ALDH1A1 (0.43) | LMNAHTTCYP1A2CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-0983222-B1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2004028548-A2 | INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS | CARBOMER, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | disclosed |
| EP-0983222-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052898-A9 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998052898-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | SCN1A 703/4885SCN2A 858/4885SCN3A 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.